Navigation Links
PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property
Date:6/27/2011

SAN CARLOS, Calif., June 27, 2011 /PRNewswire/ -- PharmacoFore, Inc., a privately held biopharmaceutical company developing next-generation abuse-resistant prescription drugs, today announced the appointment of Dr. Joseph Stauffer as Chief Medical Officer & VP, Corporate Strategy and Dr. Narinder Banait as VP, Intellectual Property.

Dr. Joseph Stauffer - Chief Medical Officer & VP, Corporate Strategy

Prior to joining PharmacoFore, Dr. Stauffer was Chief Medical Officer and Executive Vice President, Corporate Strategy at DURECT Corporation, a specialty pharmaceutical company focused on the development of pharmaceutical systems to treat chronic debilitating diseases. Prior to joining DURECT, Dr. Stauffer was at Alpharma, Inc. from 2004 to 2009, where his latest position prior to the acquisition of Alpharma by King Pharmaceuticals was as Chief Medical Officer and Senior Vice President of Clinical Research & Medical Affairs.  His responsibilities at Alpharma included oversight of all clinical pharmacology, clinical development, pharmacovigilance, medical affairs, risk management and health outcomes/pharmacoeconomics.  Dr. Stauffer led the development and regulatory efforts that resulted in the approval of EMBEDA®, an abuse-resistant formulation of morphine.  Prior to joining Alpharma, Dr. Stauffer was employed at Abbott Laboratories from 2002 to 2004 as Global Medical Director for Pain Therapeutics.  In that role, he was responsible for Phase I-III trials for Vicodin, Vicoprofen, Dilaudid, as well as novel compounds targeting neuropathic pain.  Prior to Abbott, he worked at the FDA from 2000 to 2002 as a Medical Review Officer in the Analgesic Division of the Center for Drug Evaluation and Research.  While there, he reviewed Investigational New Drug (IND) Applications and New Drug Applications (NDAs) for opiate, non-opiate, anti-inflammatory and novel pain compounds.  Dr. Stau
'/>"/>

SOURCE PharmacoFore, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. PharmacoFore, Inc. Announces Sponsorship of the 2011 CLAAD National Prescription Drug Abuse Prevention Policy Consensus Meeting on November 29, 2011 in Washington, DC
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 Vestiage, Inc. ... company focused on science-based research and development, sales ... cosmeceuticals and nutraceuticals, announced today that it is ... for the sale of Reluma Skin Illuminating Facial ... and application by sending an email to info(at)vestiageinc(dot)com ...
(Date:5/23/2013)... May 23, 2013 Venaxis, Inc. (Nasdaq:   ... on obtaining FDA clearance and commercializing its rapid, protein ... pricing of an underwritten public offering of 10,000,000 shares ... 3,500,000 shares of its common stock at an exercise ... offering price of $1.25 per share and related warrant.  ...
(Date:5/23/2013)... Patheon Inc ., a leading ... global pharmaceutical industry, will host a complimentary webinar on ... on Tuesday, June 4, 2013 at 11 a.m. Eastern ... to comply with regulations for cleaning validation. Many ... underpinning and little evaluation of risk. Some companies ...
(Date:5/23/2013)... 23, 2013 PI’s new LPS-24 ... provide 15 mm travel range with closed-loop sensor ... dimensions make these new positioners the ideal choice ... vacuum rated version is also available. , ... datasheets can be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2
... GenVault,s energy and space efficient technologies ideally suit ... create a new paradigm for eco-friendly, sustainable Biobanking ... announces the opening of its newly-formed Japanese subsidiary ... the expanding Biobanking market and its growing customer ...
... Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, today ... ophthalmic gel, 0.15%, has been accepted for review by ... is seeking approval for ganciclovir as a treatment for ... simplex virus. The FDA has issued an action date ...
... 26 Fifty percent of clinical trial management ... share high-value, proprietary company information via e-mail, while ... overnight courier (14 percent), according to a recent ... for exchanging clinical trial information with outside parties ...
Cached Biology Technology:GenVault Opens Japanese Subsidiary to Better Address Global Biobanking Market Growth 2Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 2Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 3IntraLinks Poll: Half of Clinical Trial Management Professionals Share Critical Information Via E-Mail 2
(Date:5/23/2013)... School of Public Health at Emory University, along ... have received a $4 million grant over four ... University (Health and Exposome Research Center: Understanding Lifetime ... grant awarded in the United States. , ... Institute of Environmental Health Sciences (NIEHS) of the ...
(Date:5/23/2013)... new report from the Institute of Medicine says schools ... least 60 minutes of vigorous or moderate intensity activity ... of American youth meet current evidence-based guidelines of at ... activity daily, according to the report, which was released ... nearly half of their waking hours, the committee recommends ...
(Date:5/23/2013)... when microbial pathogens are growing increasingly resistant to the ... of Wisconsin scientists has synthesized a potent new class ... staph infections. , Writing online in the Journal ... by University of Wisconsin-Madison chemistry Professor Helen Blackwell describes ... of Staphylococcus aureus , a bacterium at the ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide students with daily physical activity, IOM recommends 2University of Wisconsin chemists find new compounds to curb staph infection 2
... clumps of protein found within nerve cells are ... were first identified in the early 1900s by German ... in a protein called tau cause it to aggregate ... Normally, the tau protein is involved in the formation ...
... of cardiovascular disease, research from the Sahlgrenska Academy at the ... obesity hormones adiponectin - are also linked to osteoporosis ... is more than just bones, vertebrae and joints. In fact, ... our brain, our muscles and our fatty tissue. Stem cells ...
... D deficiency is common in Americans, and especially in ... of Health. University of Missouri researchers have found that ... vitamin D3 is safe and effective in improving their ... risk for deficiency because they tend to absorb vitamin ...
Cached Biology News:Chemical engineers help decipher mystery of neurofibrillary tangle formation in Alzheimer's brains 2Obese adolescents benefit from high-dose vitamin D supplements 2
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
... Our fastest automated perfusion system. For ... perfusion, physiology, biophysics, electrochemistry, or general ... with 1.5-4 millisecond accuracy Run ... Microprocessor-based for accuracy and flexibility ...
Mycoplasma tested...
Biology Products: